April 26, 2024

• 

[THE INVESTOR] As of Mar. 17 12:25 P.M., Sam Chun Dang Pharm declined 3.33%, compared with yesterday, to 14,500 won. It had increased 2.84% through the past month. Standard deviation, the variableness index, was 2.2% on the same period over one month.

Compared with its close competitors within the same industry, KOSDAQ, the monthly earnings rate of Sam Chun Dang Pharm was considerably higher than that of its peer group's, but its volatility within 1 month was relatively lower than that of its peer group's. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was 1.2. Compared with the KOSDAQ industry, the return-on-risk is much better than the industrial mean, -0.5, and thus the industrial comparison performance was positive.

By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.